Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

FDA-approved slower Topamax titration schedule improves tolerability

May 18, 2000

Drug may provide the basis for a new class of neuropsychiatric medications

May 17, 2000

Joint research at Japanese labs leads to design of high-affinity MDR ligands

May 17, 2000

ADIR describes preparation and use of new cyclic melatonin receptor ligands

May 17, 2000

Small phase II study of Xerecept in peritumoral brain edema yields encouraging results

May 16, 2000

Immunogenic chemokine receptor peptides prepared at Corixa for use in autoimmune diseases

May 16, 2000

Olanzapine salts with improved pharmaceutical properties

May 16, 2000

Concerta to be copromoted by Alza and McNeil for ADD/ADHD

May 16, 2000

Forest and Warner-Lambert terminate Celexa copromotion agreement

May 16, 2000

CNS-5161 being rapidly advanced to phase II for pain; development partner will be sought

May 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...